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It has been known for more than 4 decades that only
primate growth hormones are effective in primate spe-
cies, but it is only with the availability of the 2.8 Å
structure of the human growth hormone (hGH)zhGH-
binding protein (hGHBP)2 complex that Souza and co-
workers (Souza, S. C., Frick, G. P., Wang, X., Kopchick,
J. J., Lobo, R. B., and Goodman, H. M. (1995) Proc. Natl.
Acad. Sci. U. S. A. 92, 959–963) were able to provide evi-
dence that Arg-43 on the primate receptor is responsi-
ble. Here we have examined systematically the inter-
action between Arg-43 (primate receptor) or Leu-43
(non-primate receptors) and their complementary hor-
mone residues Asp-171 (primate GH) and His-170 (non-
primate hormones) in a four-way comparison involving
exchanges of histidine and aspartate and exchanges of
arginine and leucine. BAF/B03 lines were created and
characterized which stably expressed hGH receptor,
R43L hGH receptor, rabbit GH receptor, and L43R rab-
bit GH receptor. These were examined for site 1 affinity,
for the ability to bind intact cells, and for proliferative
biopotency using hGH, D171H hGH, porcine GH, or
H170D porcine GH. We find that the single interaction
between Arg-43 and His-170/171 is sufficient to explain
virtually all of the primate species specificity, and this is
congruent with the crystal structure. Accordingly, for
the first time we have been able to engineer a non-
primate hormone to bind to and activate the human GH
receptor.
The growth hormone receptor (GHR)1 is a member of the
hematopoietic cytokine receptor family, sharing common struc-
tural and functional features with receptors for prolactin,
erythropoietin, granulocyte and granulocyte-macrophage colo-
ny-stimulating factors, several interleukins, thrombopoietin,
ciliary neurotrophic factor, oncostatin M, and leptin (for re-
view, see Refs. 1 and 2). Of this family, the interaction of GH
with its receptor is the best characterized, primarily because of
the extensive structure/function studies that have been carried
out on both GH and the GHR (for review, see Ref. 1) and
because it is the only member for which the crystal structure of
the hormone-receptor complex is known (3). Both crystal struc-
ture and solution studies support the concept that two identical
receptor subunits bind the helix bundle hormone through sim-
ilar loop determinants on the receptor b-sandwich structures.
The hormone is captured by receptor 1 through binding to
determinants located in a 900-Å2 patch encompassing helices 1
and 4 and the unstructured loop between helices 1 and 2. Eight
key residues account for 85% of the binding energy, with elec-
trostatic interactions governing the approach of hormone to the
receptor binding site (4, 5). Electrostatic interactions are also
important specificity determinants because 5 of the 7 residues
that were modified to enable prolactin to bind to the GH recep-
tor with high affinity involved charged residues (6).
GHs from humans and monkeys (primate GHs) are unique in
that they are able to bind with and activate non-primate GHRs
as well as primate GHRs, whereas the GHs from non-primates
are ineffective in primates (for review, see Ref. 7). To elucidate
which residues on the receptor are responsible for this species
specificity of binding, sequence alignment analysis was per-
formed on human GHR (hGHR) and a number of non-primate
GHRs in conjunction with an examination of the crystal struc-
ture of the GHz(GHBP)2 complex. Of residues within the five
major loops involved in hormone binding (2), the interaction
between Arg-43 of the human receptor and Asp-171 of the
human hormone is striking because in non-primate receptors
this position is replaced by leucine, and histidine occupies the
place of aspartate in non-primate hormones (the equivalent
position in porcine and bovine GH is 170). An unfavorable
charge repulsion/steric hindrance between hormone His-170
and receptor Arg-43, rather than a favorable salt bridge be-
tween this arginine and primate hormone Asp-171, could be an
important element in the inability of non-primate hormones to
bind to the human receptor. Accordingly, we previously under-
took site-directed mutagenesis at position 43, converting
Leu-43 of the rabbit receptor to arginine (L43R rbGHR), and
compared the ability of wild type and mutant receptors to
discriminate between binding of hGH and bovine GH (8). We
were disappointed to find that the L43R rbGHR mutant was
able to bind human GH (hGH) and bovine GH (bGH) with
almost identical affinity, indicating that it was not the species
specificity determinant (8). However, a more recent study on
bovine and rat GHRs by Souza et al. (9) has revealed that
conversion of leucine to arginine at position 43 of these recep-
tors severely abrogated the binding ability of bGH and also
reduced its signaling ability. Based on the crystal structure of
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the GHz(GHBP)2 complex, Souza et al. (9) again proposed that
an unfavorable interaction between His-170 on non-primate
GH and Arg-43 on the human receptor accounts for primate
specificity of binding.
In this study, we have sought to resolve this conflict. We
have examined the binding and signaling characteristics of
rabbit and human GHRs with human, porcine, and bovine GHs
as well as the effect of exchanging both the receptor leucine for
arginine and the hormone histidine for aspartate. This has
allowed us to bind a non-primate GH to the human receptor for
the first time and to resolve the conflict between our previous
study and that of Souza et al. (9).
EXPERIMENTAL PROCEDURES
Hormone Mutagenesis and Expression—Preparation of recombinant
pGH and H170D pGH has been described previously (10, 11). Recom-
binant bGH was a gift from Cyanamid (Princeton NJ). Human GH and
the D171H hGH analog were expressed in Escherichia coli and purified
to greater than 98% homogeneity (by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis in the manner described previously (10),
except that the pH of the refolding buffer and Q-Sepharose loading
buffer was 8.2. The D171H mutation was introduced into the coding
sequence of the hGH cDNA using the Altered Sites mutagenesis proce-
dure (Promega). In this procedure, an oligonucleotide encoding the
desired mutation is annealed to single strand hGH-pSelect, and the
complex is incubated with T4 DNA polymerase and T4 DNA ligase
(Promega) to produce double stranded circular plasmid according to
instructions from Promega. This was then subcloned into the pC611
vector (kindly provided by BresaGen, Adelaide, Australia) for expres-
sion, as described before (10). The mutation was confirmed by dideoxy
sequencing (U. S. Biochemical Sequenase kit) of the complete D171H
coding region. Hormone concentrations were determined spectrophoto-
metrically using an extinction coefficient of e280 5 18,200 M
21 cm21.
Receptor Mutagenesis—Site-directed mutagenesis was undertaken
on the rabbit GHR (rbGHR) and hGHR cDNA using the Altered Sites
mutagenesis procedure as described previously (8). Mutant sequences
were then subcloned into the pECE expression vector. Creation of
rabbit L43R and human R43L GHR mutants and the absence of other
coding sequence changes were verified by dideoxy sequencing.
Establishment of Cell Lines Expressing GHRs—The interleukin-3-
dependent cell line BAF/B03 was a gift from Dr. Tom Gonda (Institute
for Medical and Veterinary Sciences, Adelaide). Cells were routinely
passaged in 5% CO2, at 37 °C, in RPMI 1640 medium supplemented
with 5 mg/ml gentamicin, 10% serum supreme (a fetal bovine serum
alternative supplied by Biowhittaker through Edward Keller Australia
Ltd., Underwood Queensland) and 50 units/ml interleukin-3 (generous
gift from Dr A. Hapel, John Curtin School of Medical Research, Aus-
tralian Capital Territory, Australia). Mid confluent BAF/B03 cells (200
ml of 2.5 3 107/ml growth medium) were transfected by electroporation
with GHR cDNA and pNeo plasmid at a ratio of 20:1 in a manner
identical to that described in Ref. 11. After electroporation, transfec-
tants were selected by treatment with G418 at 1.2 mg/ml followed by
selection of single cells and clonal expansion.
Determination of Affinity Constants for GHs and Characterization of
Expressed GHRs—Equilibrium binding constants for all GHs were de-
termined with the appropriate cell line in physiological binding buffer
(8) using 125I-hGH as described in Ref. 10. Assays were done at 4 °C to
block receptor internalization, with equilibrium being reached by 18 h.
The number of surface-expressed receptors and the hormone binding
affinity for each cell line were determined using cells grown in GH-free
RPMI 1640 medium containing 1 mg/ml gentamicin, 5% serum su-
preme, and 50 units/ml of interleukin-3. Binding assays were also
performed on solubilized cell extracts as follows. Cells were lysed with
0.3% (v/v) Triton X-100 in physiological binding buffer in the presence
of 5 mg/ml MAb 5 and microcentrifuged at 15,000 rpm for 15 min to
recover the solubilized receptors. Equilibrium binding assays (in the
presence of MAb 5 (AGEN Ltd., Acacia Ridge, Queensland) at 5 mg/ml)
were then undertaken on solubilized cell extracts for 18 h at 4 °C, with
bound/free separation by polyethylene glycol precipitation, as in Ref. 12.
MAb 5 has been shown to block receptor dimer formation through
binding to the dimerization domain residues (13) so that this binding
assay measures binding to receptor 1 only. Binding data were processed
by Scatchard analysis with the LIGAND program (Elsevier Biosoft).
Proliferation Assays—MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide) cell viability assays were performed in the
manner described in Ref. 11 using the GHR-expressing BAF/B03 cells
described above. Because the magnitude of GH responsiveness of these
GHR-expressing cell lines is related to the level of receptor expression,2
it was necessary to plate clonal cell lines at different concentrations to
obtain comparable response. BAF/B03-rbGHR cells (expressing wild
type rabbit GHR), BAF/B03-hGHR cells (expressing wild type human
GHR), and BAF/B03-L43R rbGHR cells (expressing L43R rbGHR) were
plated out at 2.5 3 104 cells/well, whereas BAF/B03-R43L hGHR cells
(expressing R43L hGHR) were plated at 6 3 104 cells/well.
Crystal Structure Analysis—The complete coordinates of the
hGHz(hGHBP)2 complex were obtained from the PDB data base (acces-
sion number 3hhr). The homology-modeled pGHz(rbGHBP)2 complex
was obtained with the Homology program (Biosym Technologies, San
Diego) with the assistance of Ross Brinkworth, Drug Design Center,
University of Queensland (10). Crystal structure measurements were
made with the Insight II program (Biosym Technologies), and molecu-
lar dynamics and energy minimizations were done using the Discover
module.
RESULTS
Characterization of Cell Lines Expressing GHRs—BAF/B03
cells were preferred over FDC-P1 cells in this study as we have
found that they express GHRs at a higher level than FDC-P1
cells. Whole cell Scatchard analysis (at least three independent
assays where 125I-hGH was displaced by unlabeled hGH for
each cell line) revealed an affinity for hGH of of 2.9 6 0.2 3 109
M21 with 7,419 6 777 receptors/cell for BAF/B03-hGHR cells,
an affinity of 3.3 6 0.2 3 109 M21 with 3,164 6 528 receptors/
cell for BAF/B03-R43L hGHR cells, an affinity of 6.0 6 0.6 3
109 M21 with 7,285 6 618 receptors/cell for BAF/B03-rGHR
cells, and an affinity of 5.0 6 0.4 3 109 M21 with 2,852 6 455
receptors/cell for BAF/B03-L43R rGHR cells. No specific 125I-
2 S. W. Rowlinson, S. N. Behncken, and M. J. Waters, unpublished
observations.
TABLE I
Fold changes of various hormones with wild type hGHR (relative to wild type hGH)
Fold change values were derived from experiments on all five hormones performed simultaneously with the same cell/receptor preparation (see
“Experimental Procedures”). Arrows indicate increase or decrease relative to wild type hGH (shown as unity). Whole cell binding affinities were
determined by Scatchard analysis, and fold changes were calculated (except for pGH) within each experiment. Because of low receptor level and
low affinity for some hormones, values for the solubilized receptors (and whole cell binding to pGH) were determined from ED50 estimates
calculated from a specific binding curve. Proliferative ability was determined by comparing ED50 estimates from a dose-response curve (a decrease
in proliferative ability is implied from an increase in ED50). Results are the mean of at least three independently calculated fold change values with
S.E. shown. The absolute affinity and ED50 values for wild type hGH are shown in parentheses (also determined from at least three independent
experiments). The affinity of bGH for the solubilized receptors was not determined.
Hormone
Affinity
Proliferative ability
Solubilized receptor Whole cell
hGH 1 (Ka 5 1.18 6 0.13 3 10
9 M21) 1 (Ka 5 2.50 6 0.15 3 10
9 M21) 1 (ED50 5 2.09 6 0.36 3 10
211 M)
D171H hGH 36.7 6 1.12 2.1 6 0.32 1.9 6 0.32
pGH .10,0002 3,904.5 6 828.72 2,342.2 6 390.32
H170D pGH 32.3 6 1.92 24.5 6 3.92 14.0 6 2.22
bGH NDa 314.1 6 46.82 235.8 6 64.22
a ND, not determined.
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hGH binding was seen in nontransfected BAF/B03 cells. The
fact that ED50 values for proliferative biopotency are around
0.05 3 1029 M (Tables I–IV, see below) suggests that there is a
substantial number of spare receptors in these lines.
Binding and Signaling with the Human Receptor—Table I
presents the combined data for wild type human GH receptor-
expressing cells, and Fig. 1, A–C, presents representative data
in graphic form. First, it can be seen that substitution of his-
tidine for aspartate at position 171 of hGH has only a small
effect (about a 2-fold reduction) on binding in the whole cell
assay and on biopotency. However, in the solubilized assay
where dimerization cannot occur, this substitution is seen to
have a considerable impact on site 1 affinity (about a 40-fold
decrease). Porcine GH is seen to bind very poorly in the whole
cell assay (about 4,000-fold less than hGH) and to be very
poorly effective in the bioassay (about 2,300-fold less). In the
solubilized receptor assay, pGH effectively does not bind to the
hGHR. However, substitution of aspartate for histidine at po-
sition 170 of pGH results in a hormone that is only 24-fold less
than hGH in whole cell binding affinity and 14-fold less in
biopotency. This is essentially a result of increased site 1 in-
teraction because in the solubilized receptor assay the affinity
of H170D pGH for the hGHR is only about 30-fold lower than
hGH.
The converse study, where Arg-43 in the hGHR is replaced
by a leucine, shows that D171H hGH now binds and signals as
effectively as wild type hGH (Table II). Against the R43L
hGHR, pGH now behaves similarly to the way H170D pGH
does against the wild type human receptor, i.e. its whole cell
affinity is about 15-fold less than hGH, its biopotency is about
14-fold less than hGH, and in the solubilized receptor assay its
affinity is only 30-fold less than hGH. Thus, mutation of either
receptor Arg-43 to non-primate leucine or mutation of hormone
Asp-171 to non-primate histidine has a very similar effect on
magnitude of binding affinity and biopotency. This effect is also
seen with another non-primate GH, bGH, which binds and acts
poorly against the wild type human receptor but is quite effec-
tive (3–4-fold less than hGH) against human receptor with
leucine in position 43.
Binding and Signaling with the Non-primate Receptor—Ta-
ble III presents the combined affinity and biopotency data for
the same GH analogs, but in this case against the rbGHR. It
can be seen that replacement of Asp-171 of hGH with histidine
has little effect on binding or bioactivity. Again there is a small
loss in solubilized receptor affinity, suggesting that aspartate is
slightly more effective in this position against receptor Leu-43,
but clearly either histidine or aspartate sits well against a
leucine at receptor residue 43. Porcine GH is considerably less
effective than hGH against the rabbit receptor in accord with
our previous data (11). This would appear to be primarily a
result of poor site 1 interactions because the affinity of pGH in
the solubilized receptor assay is markedly less than hGH. This
poor interaction is evidently not a result of hormone residue
170 interactions because substituting aspartate for histidine at
this position again improves solubilized receptor affinity by
only 2–3-fold, against leucine at position 43. Bovine GH is seen
to bind and act considerably more effectively than pGH against
the rabbit receptor (Table III).
Creation of a “humanized” rabbit receptor by replacing
Arg-43 with leucine provides the final argument for the impor-
tance of this interaction in determining primate specificity
(Table IV). As with the wild type rabbit receptor, hGH binds
more strongly than it does against its own receptor. However,
replacing Asp-171 with histidine markedly decreases (about
50-fold) site 1 affinity. Evidently strong site 2 interactions are
able to compensate in that the whole cell affinity and biopo-
tency are not markedly (about 2-fold) different from wild type
hGH. Porcine GH now binds very poorly in the whole cell assay
and effectively does not bind in the solubilized receptor assay.
Biopotency is also very markedly reduced. This situation is
FIG. 1. Representative comparisons of hGH (l), D171H hGH
(3), pGH (f), and H170D pGH () measured against wild type
hGHR. Each symbol is representative of at least three independent
experiments (see “Experimental Procedures”). Panel A, linear portion of
a specific binding curve for each hormone binding to the solubilized wild
type hGHR (incubated with MAb 5). Panel B, linear portion of a specific
binding curve for each hormone binding to whole cells expressing
hGHRs. Panel C, proliferation dose-response curve for each hormone as
measured by MTT assay on cells expressing wild type hGHR.
Species Specificity of Growth Hormone Binding 27079
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
effectively reversed by substitution of His-170 with aspartate,
so that this analog now behaves similarly to pGH binding in its
binding to the wild type rabbit receptor.
In support of both our previous study (8) and the study of (9),
bovine GH binding to the L43R rabbit receptor is only about
2.5-fold less than binding to wild type rabbit receptor, yet in the
solubilized receptor assay its site 1 binding is very poor (700-
fold less), and its biopotency is reduced quite strongly (about
35-fold).
Proliferative Bioassays—MTT assays were used as described
previously (11) to compare the biopotencies of the various hor-
mone preparations against wild type or mutant GHR-express-
ing cells. Because two GHRs interact with one GH molecule
and because they use virtually the same residues to interact
with the hormone at either site 1 or site 2 (3, 14), it is not
possible to compare the relative biopotencies between wild type
and mutant cell lines because of the uncertainty that the mu-
tation could be affecting the bioactivity through site 2 interac-
tions and not site 1 interactions. For this reason the biopoten-
cies of the GHs with different cell lines are compared relative to
wild type hGH.
Bioassay with hGH Receptor-expressing Lines—With the
hGHR-expressing cell line, the D171H hGH mutant was simi-
lar to wild type in its biopotency (see “Discussion”). The non-
primate GHs, bGH and pGH, were very poor agonists for this
cell line, showing 235- and 2,342-fold lower biopotency relative
to hGH. For pGH, the introduction of the H170D mutation
improved the biopotency such that it is only 14-fold lower than
that of hGH, an improvement of greater than 150-fold. Similar
improvements in biopotency were observed with bGH and pGH
upon the introduction of the R43L mutation in the hGHR. In
this case, the biopotency of these hormones relative to hGH
became only 3.6- and 13.5-fold lower than hGH, an improve-
ment of more than 80- and 150-fold, respectively, when com-
pared with the wild type hGHR-expressing cell line. In con-
trast, the H170D pGH analog exhibited similar biopotencies
against the wild type hGHR- and R43L hGHR-expressing cell
lines, indicating that aspartate at this location is equally well
tolerated against either arginine or leucine.
Bioassay with rbGHR-expressing Lines—With the wild type
rabbit receptor, hGH, D171H, and bGH have similar high
potencies. pGH is a poor agonist, and H170D pGH is reduced
further in potency by a factor of 2. Introduction of Arg-43 leads
to a marked fall in biopotency for pGH and bGH but no change
in biopotency for H170D pGH. Again, the D171H hGH analog
appears able to compensate for loss of site 1 affinity against the
L43R rbGHR.
Correlations between Bioactivity (ED50) and Affinity—Corre-
lation analysis using all of the data in Tables I–IV (except for
for the bGH/L43R combination) is shown in Fig. 2. It can be
seen that site 1 affinity does not correlate with biopotency,
whereas whole cell affinity correlates very well (r 5 0.99, p ,
0.001). This indicates that the whole cell assay measures for-
mation of the trimeric signaling complex.
TABLE II
Fold changes of various hormones with R43L hGHR (relative to wild type hGH)
For experimental details, see legend of Table I.
Hormone
Affinity
Proliferative ability
Solubilized receptor Whole cell
hGH 1 (Ka 5 6.32 6 1.76 3 10
9 M21) 1 (Ka 5 3.33 6 0.21 3 10
9 M21) 1 (ED50 5 4.54 6 0.50 3 10
211 M)
D171H hGH 1.7 6 0.31 1.1 6 0.22 1.2 6 0.31
pGH 27.2 6 7.92 14.5 6 2.12 13.5 6 3.02
H170D pGH 4.6 6 1.12 20.8 6 1.42 15.3 6 3.92
bGH NDa 3.5 6 0.62 3.6 6 1.52
a ND, not determined.
TABLE III
Fold changes of various hormones with wild type rbGHR (relative to wild type hGH)
Fold change values were derived from experiments on all five hormones performed simultaneously with the same cell/receptor preparation (see
“Experimental Procedures”). Arrows indicate increase or decrease relative to wild type hGH (shown as unity). Whole cell and solubilized receptor
binding affinities were determined by Scatchard analysis, and fold changes were calculated within each experiment. Proliferative ability was
determined by estimating the ED50 from a dose-response curve (a decrease in proliferative ability is implied from an increase in ED50). Results are
the mean of at least three independently calculated fold change values with S.E. shown. The absolute affinity and ED50 values for wild type hGH
are shown in parentheses (also determined from at least three independent experiments). The affinity of bGH for the solubilized receptors was not
determined.
Hormone
Affinity
Proliferative ability
Solubilized receptor Whole cell
hGH 1 (Ka 5 5.38 6 0.97 3 10
9 M21) 1 (Ka 5 5.95 6 0.57 3 10
9 M21) 1 (ED50 5 5.73 6 0.50 3 10
211 M)
D171H hGH 1.5 6 0.22 1.2 6 0.11 1.6 6 0.32
pGH 179.2 6 72.02 8.3 6 1.12 5.4 6 0.42
H170D pGH 40.4 6 9.92 20.6 6 3.12 11.6 6 0.72
bGH 3.5 6 0.92 2.0 6 0.62 1.3 6 0.22
TABLE IV
Fold changes of various hormones with L43R rbGHR (relative to wild type hGH)
For experimental details, see legend of Table III.
Hormone
Affinity
Proliferative ability
Solubilized receptor Whole cell
hGH 1 (Ka 5 7.53 6 0.78 3 10
9 M21) 1 (Ka 5 4.99 6 0.41 3 10
9 M21) 1 (ED50 5 3.68 6 0.68 3 10
211 M)
D171H hGH 52.3 6 15.12 1.7 6 0.22 1.9 6 0.32
pGH .10,0002 125.5 6 26.92 256.0 6 36.32
H170D pGH 65.2 6 19.52 20.6 6 2.12 12.1 6 2.72
bGH 690.8 6 72.42 2.6 6 0.12 37.4 6 8.62
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DISCUSSION
This is the first comprehensive study of the structural basis
for primate specificity of binding by the hGHR. Our four-way
mutational analysis is entirely consistent with the concept,
originally proposed by Nicoll et al. (15), that a hindrance de-
terminant is responsible for restricting receptor binding to
primate growth hormones. As can be seen in Fig. 3, in the case
of non-primate hormones, the steric hindrance resulting from
the incompatibility of histidine at hormone residue 170 and
arginine at receptor residue 43 is presumably exacerbated by
repulsive interactions between these basic residues. In the case
of pGH, substitution of this single histidine with aspartate
results in a greater than 200-fold increase in binding affinity
and potency, to around 1/20 of hGH (Table I). Conversely,
substitution of receptor Arg-43 with non-primate leucine in the
hGHR allows pGH to bind, again with around 5% of the affinity
and potency of hGH (Table II). With the R43L hGHR mutant,
substitution of His-170 with aspartate now results in only a
minor increase in site 1 affinity and no change in biopotency.
The complementary mutation in the rbGHR (L43R) sets up
primate type specificity in that pGH binds and acts weakly,
and only “humanized” pGH (H170D) is able to bind and act
reasonably effectively on this receptor mutant (Tables III and
IV). In the light of these findings, it is interesting to note that
ovine and bovine placental lactogens, which are unique among
non-primate hormones in being able to bind to the human
receptor with high affinity (16) despite only a 25% homology to
hGH, possess serine at equivalent position 171, unlike any
other GHs.
With other class 1 cytokine receptors displaying species re-
striction in binding (e.g. the leukemia inhibitory factor receptor
(17) or the granulocyte-macrophage colony-stimulating factor
receptor (18)) mutagenesis has revealed that several residues
are responsible. Although the evidence presented here sup-
ports a central role for His-170 in determining binding speci-
ficity, other species-specific determinants may reside in the
unstructured loop between helices 1 and 2, based on the hom-
olog scanning mutagenesis study of Cunningham et al. (19). In
that study, while substituting pGH residues 164–191 into hGH
abolished binding to the hGHR binding domain, substitution of
pGH residues 54–74 resulted in a 17-fold decrease in affinity.
Although these data can be interpreted as indicating other
species determinants, it must be said that pGH is poorly effec-
tive even against the non-primate rabbit receptor (Table III), so
the residual 17-fold loss in affinity may be a result of generally
poorer binding of pGH to GH receptors.
The data presented here provide strong support both for our
original postulate (8, 20) that receptor Arg-43 is a primate
specificity determinant, and for the results of Souza et al. (9),
wherein mutation of Leu-43 of mouse or bovine receptor to
arginine resulted in primate type specificity. Why then, is
bovine GH binding to intact cells only slightly decreased in
affinity when tested against the L43R rbGHR (Table IV and
Ref. 8)? As can be seen from Tables III and IV, bGH binds very
poorly to the solubilized L43R rabbit receptor (200-fold lower
affinity than for wild type rbGHR), yet it is unusual in that its
affinity in the whole cell assay is essentially unchanged rela-
tive to wild type rabbit receptor. The biopotency falls between
these extremes (29-fold lower than against wild type rbGHR).
These apparently contradictory observations may be resolved
by the unusually high site 2 affinity reported for bGH binding
to its receptor (21), which would strongly favor formation of the
ternary complex over the 18 h at 4 °C required to reach binding
equilibrium. That bGH binding to primate receptor is re-
stricted by the same mechanism as pGH is apparent in Tables
I and II, where substitution of leucine for Arg-43 of the human
receptor is able to increase binding 90-fold and biopotency
65-fold.
The interactions involving human receptor Arg-43 and Asp-
171 of hGH are shown in Fig. 3A, and those of rabbit receptor
Leu-43 and His-170 of pGH, homology modeled from the hu-
man coordinates, are shown in Fig. 3B. It can be seen that the
human receptor-hormone interaction is stabilized by a salt
bridge between receptor Arg-43 and Asp-171 and a hydrogen
bond between Arg-43 and hormone Thr-175. The alkyl portion
of Arg-43 also shares a hydrophobic interaction with Trp-169.
In addition, there may be a weak hydrogen bond between
Asp-171 and the Ne1 of receptor Trp-104. Because of the ex-
tensive network of interactions involving Arg-43, it is to be
expected that alanine substitution would result in a substan-
tial decrease in affinity, and a loss in binding free energy of
around 2 kcal/mol was reported in Ref. 5. However, as can be
seen from Table II, leucine substitution results in no significant
change in site 1 affinity, leading to the conclusion that guanido
headgroup interactions are not as important as the hydropho-
bic interaction with receptor Trp-169, which presumably still
occurs with leucine at residue 43. It has been reported that
alanine substitution of Asp-171 results in an approximately
4-fold loss in affinity (4), presumably because of the loss of the
FIG. 2. Correlation plots of affinity against bioactivity. Panel A,
fold changes in whole cell affinity for each hormone (relative to wild
type hGH) plotted against fold changes in proliferative ability (relative
to wild type hGH). Data are taken from Tables I–IV. Panel B, fold
changes in site 1 affinity for each hormone (relative to wild type hGH)
plotted against fold changes in proliferative ability (relative to wild type
hGH). Data are taken from Tables I–IV.
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salt bridge with Arg-43 and the weak hydrogen bond with
receptor Trp-104. Substitution of histidine at this position re-
sults in a substantial loss in site 1 affinity (37-fold) as a result
of steric hindrance and repulsive interactions with Arg-43.
However, with the Leu-43-substituted human receptor such
hindrance is removed, and essentially no change in site 1
affinity is seen relative to wild type hGH when histidine is
introduced at residue 171, in contrast to the 4-fold loss seen
with alanine substitution in binding to wild type hGHR
(above). It is plausible that histidine substitution at hGH 171
results in a new hydrogen bond with the Ne1 of receptor Trp-
104 (Fig. 3B), a bond that is presumably present in all non-
primate receptor interactions. This is supported by the finding
that the site 1 affinities of wild type hGH and of D171H hGH
are the same against the rabbit receptor (Table III).
In the current study we have elected to use three kinds of
assays to investigate the GH-receptor interaction. The solubi-
lized receptor binding assay, carried out in the presence of the
dimerization blocking antibody MAb 5 (14), provides a measure
of site 1 affinity for the intact receptor. The whole cell binding
assay, carried out at 4 °C to prevent internalization, is in-
tended to provide a measure of formation of the ternary com-
plex and as such includes avidity and membrane geometry
effects (22). The proliferation bioassay, performed on the same
cell lines as for the two binding assays, provides accurate
biopotency data with full-length human and rabbit receptors.
Inspection of Tables I–IV shows that generally the whole cell
binding affinity is closely related to the bioassay value in terms
of rank order and magnitude (Fig. 2A, correlation coefficient
0.99, p , 0.001, excluding bGH with L43R rGHR), whereas site
1 affinity does not correlate with biopotency (Fig. 2B).
With D171H hGH, large changes in site 1 affinity do not
manifest as large changes in biopotency, either with the human
or rabbit receptor. This may indicate a strong propensity for
hGH to form site 2 interactions. The pGH-hGH receptor inter-
action on the other hand, does not show a large difference
between site 1 affinity and whole cell binding or biopotency,
which could be a result of weak site 2 interactions. With the
rabbit receptor, rank order and magnitude of whole cell affinity
and biopotency again correlate well, except in the case of bGH
and the L43R rbGHR, for the reasons discussed above. Based
on the results with wild type pGH binding to the rabbit recep-
tor (i.e. a sizable disparity between site 1 affinity and whole cell
affinity), one could propose that site 2 interactions here are
stronger than for the R43L human receptor. For reasons that
are not clear, this disparity is not as marked with the H170D
pGH analog. Further high performance liquid chromatography
studies with purified human and rabbit GHBPs are needed to
provide a quantitative basis for these proposals, but it would
appear that this analog is not as effective as wild type in
inducing trimer formation. What is clear is that substantially
decreasing the affinity of hGH (50-fold) has little effect on
biopotency, whereas with pGH a marked effect on biopotency is
seen with altered affinity. This is concordant with the finding of
FIG. 3. Side chain interactions in
the critical species-determining re-
gion of GH/GHR. Panel A, hGH side
chains D171 and T175 interacting with
hGHR side chains R43, W104, and W169
taken from the hGH(hGHBP)2 crystal
structure (3). Distances between particu-
lar atoms are as follows: Arg-43 Nh2 to
Thr-175 Og1 5 3.30 Å, Arg-43 Nh1 to
Asp-171 Og1 5 3.30 Å, and Trp-104 Ne1
to Asp-171 Od2 5 3.1 Å, indicating likely
hydrogen bonds and salt bridges. Panel B,
pGH side chains His-170 and Thr-174 in-
teracting with rbGHR side chains Leu-43,
Trp-104, and Trp-169 taken from the ho-
mology-modeled structure based on the
hGHz(hGHBP)2 crystal structure (10).
The distance between Trp-104 Ne1 and
His-170 Nd1 is 3.2 Å, and the angle be-
tween Trp-104 Ne1, Trp-104 He1, and
His-170 Nd1 is 144.4°, indicating a possi-
ble hydrogen bond. Atoms are colored as
follows: carbon, green; oxygen, red; nitro-
gen, blue. Panel C, hGH side chain Asp-
171 and hGHR side chain Arg-43 (both
red) from hGHz(hGHBP)2 crystal struc-
ture (3) superimposed over pGH side
chain His170 and rbGHR side chain
Leu-43 (both blue) from the homology-
modeled pGH/rbGHR structure (10)
showing the unfavorable interaction that
would occur between pGH His-170 and
hGHR Arg-43 (distance between His-170
Ne2 and Arg-43 Nh1 would be 1.98 Å).
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(13) that large changes in site 1 affinity of hGH do not manifest
as large changes in biopotency using a GH/granulocyte colony-
stimulating factor receptor chimera-expressing myeloma line.
However, our findings are also consistent with our previous
finding (11) that changes in site 1 binding determinants of pGH
do result in substantial changes in biopotency, such that a
5-fold increase in affinity and biopotency over wild type pGH
was seen with the C181S(del 183–191) site 1 mutant. Accord-
ingly, it is possible to improve substantially the biopotency of
pGH at least, by increasing site 1 affinity.
Given the incompatibility of His-170 and receptor Arg-43 and
its compatibility with leucine (Fig. 3C), the likely evolutionary
scenario is a single base mutation of the histidine to aspartate,
followed by single base change of receptor leucine to arginine.
The fact that aspartate is present at this position in all five
primate GH genes indicates that the initial event must have
occurred very early in primate evolution. Based on Tables I and
II, there does not appear to be any particular advantage in
selection of arginine at position 43 relative to leucine other
than a 2-fold increase in proliferative potency. In the the re-
ceptor 2 binding site, Arg-43 forms a hydrogen bond with hGH
Asn-12 (3), although the mutagenic analysis of Ref. 14 shows
that this provides minimal binding energy. The prolactin re-
ceptor has lysine in the equivalent position, but this is not a
binding element (23).
In conclusion, it has been possible to create a non-primate
hormone with the ability to bind to and activate the human
receptor by mutating one residue. The structural basis for
primate specificity resides in the incompatibility of this residue
with a hindrance determinant on the primate receptor, evident
in the crystal structure of the hormone-receptor complex. It is
salutary that although the strongest positive interaction in
hGH contributes 20-fold to the affinity (24), a single unfavor-
able interaction can reduce the affinity of pGH more than
300-fold and its biopotency more than 160-fold.
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